3-Amidinophenylalanine-derived matriptase inhibitors can modulate hepcidin production in vitro

Erzsébet Pászti-Gere1 · Gergely Szombath1 · Michael Gütschow2 · Torsten Steinmetzer3 · András Székács4

Received: 29 July 2019 / Accepted: 25 September 2019 / Published online: 28 October 2019
© The Author(s) 2019

Abstract
Matriptase-2 (MT-2) is a type II transmembrane serine protease and predominantly attached to the surface of hepatocytes. MT-2 decreases the production of hepcidin, a key regulator of iron homeostasis. In this study, the effects of four 3-amidinophenylalanine-derived combined matriptase-1/matriptase-2 (MT-1/2) inhibitors (MI-432, MI-441, MI-460, and MI-461) on hepcidin production were investigated in hepatocyte mono- and hepatocyte-Kupffer cell co-cultures. In MI-461-treated cell cultures, the extracellular hydrogen peroxide contents and the interleukin-6 and -8 (IL-6 and IL-8) levels were determined and compared to controls. Hepcidin overproduction was observed in hepatocytes upon treatment with MI-432, MI-441 and MI-461 at 50 μM. In contrast, extracellular hydrogen peroxide levels were not elevated significantly after matriptase inhibition with MI-461. Furthermore, MI-461 did not induce increases in IL-6 and IL-8 levels in these hepatic models. A model of the binding mode of inhibitor MI-461 in complex with MT-2 revealed numerous polar contacts contributing to the nanomolar potency of this compound. Based on the in vitro data on hepcidin regulation, treatment with MI-461 might be valuable in pathological states of iron metabolism without causing excessive oxidative stress.

Keywords Matriptase inhibitors · Hepatocytes · Hepcidin · Hydrogel matrix · Extracellular ROS

Introduction
Hepcidin is mainly produced in the liver and acts as a key regulator of iron homeostasis. It prevents excessive iron from entering the blood circulation via inhibiting the absorption of nutritional iron from enterocytes and suppressing the release of iron. When the blood iron concentration is high, hepcidin production in the liver becomes elevated and contrarily, in the case of the iron shortage, the hormone secretion decreases significantly leading to an enhanced iron transport (Ganz and Nemeth 2012).

Thus, hepcidin prevents iron overload (Knutson et al. 2005) which could lead to the formation of reactive oxygen species (ROS) or to severe damages to subcellular components such as electron transport chain of respiration or mitochondrial DNA content. Furthermore, the rapid iron-lowering ability of hepcidin seems to be a part of the conserved evolutionary responses against pathogenic infections, which restricts the access of bacteria to iron sources essential for their further survival (Ganz and Nemeth 2012; Gao et al. 2009). Hepcidin synthesis in the liver is upregulated by increasing levels of plasma iron supported by the fact that iron-transferrin saturation can stimulate transcription of the hepcidin encoding hepcidin antimicrobial peptide (HAMP) gene.

In the case of anemia of inflammation or in the case of prolonged conditions, anemia of chronic disease, macrophages do not release appropriate amount of iron into the bloodstream due to the antiinfectious function of hepcidin causing manifested systemic iron shortage (Ganz and Nemeth 2012). Several studies were performed to establish a relationship between hepcidin secretion and pathogen-provoked inflammatory responses. Administration of lipopolysaccharide (LPS) could lead to elevation in hepcidin-encoding mRNAs in hepatocytes and in mice (Pigeon et al.
Similar results were detected in mice exposed to *Candida albicans* and in human hepatoma cell lines infected with influenza A virus (Armitage et al. 2012). IL-6 seemed to be a key mediator among pro-inflammatory cytokines in the initiation for hepcidin overproduction in LPS-triggered inflammation, as application of IL-6 neutralizing antibodies could significantly decrease the synthesis of hepcidin mRNA. In accordance, IL-6 applied in infusions could enhance hepcidin amounts detected in human urine within few hours (Nemeth et al. 2004).

Hepcidin level is reduced in hemolytic anemia and anemias with ineffective erythropoiesis. Hypoxia can trigger the erythropoiesis via erythropoietin (EPO) synthesis in kidney and liver resulting in significant suppression of hepcidin; however, the main factor in hepcidin regulation is the iron load of serum transferrin, and not the effect of EPO (Piperno et al. 2011).

Hepatic oxidative stress as a consequence of excessive alcohol consumption or viral infections can inhibit hepcidin production and lead to iron overload which can further deteriorate the already existing pathophysiological conditions (Fujita et al. 2007; Harrison-Findik 2007).

Type II transmembrane serine proteases (TTSPs) modulate proteolytic processes on cell surfaces. The TTSPs can be divided into four subfamilies, the matriptase, the hepsin/TMPRSS, the corin, and the HAT/DESC family. All of these proteases possess a cytoplasmic N-terminal segment, followed by a transmembrane domain, a middle multidomain-like stem region of variable lengths, and a C-terminal trypsin-like protease domain (Bugge et al. 2009). Matriptase-2 (MT-2 or TMPRSS6) similarly to matriptase-1 (MT-1) is bound to cell membrane, and they are both capable of degrading extracellular matrix (ECM) proteins. MT-2 is mainly found in human adult and embryonic liver.

Moreover, an extrahepatic occurrence of MT-2 encoding mRNAs was detected in kidney and in uterine of mice (Hooper et al. 2003). MT-2 takes part in the suppression of hepcidin production via cleavage and decomposition of hemojuvelin (HJV). In the liver, bone morphogenetic protein (BMP) pathway acts as one of the key regulators for hepcidin transcription thus for the iron metabolism. These findings were supported by the fact that hepcidin responses to the acute and to the chronic iron loading were impaired upon loss of these molecules (Babitt et al. 2003; Huang et al. 2005; Corradini et al. 2011). It was also proven that the catalytic domain together with the stem region of MT-2 is necessary for the effective inhibition of hepcidin expression. TMPRSS6−/− mice have a dysfunctional MT-2 due to a deficiency in the catalytic ectodomain, and it was observed that iron deprivation itself did not induce elevated iron absorption by enterocytes in mice with mutant MT-2 (Du et al. 2008). TMPRSS6−/− mice with MT-2 deficiency suffered from microcyter hypochrom anemia accompanied by alopecia, hair follicular dystrophy, and hyperkeratosis. This condition could be improved with parenteral iron-dextran treatment suggesting the potential impact of MT-2 on iron homeostasis (Folgueras et al. 2008). Accordingly, inhibition of MT-2 has been proposed as a new therapeutic opportunity to treat iron overload diseases (Sisay et al. 2010; Stimberg and Gütschow 2013; Maurer et al. 2012).

In human patients and mice with iron-refractory iron deficiency anemia (IRIDA), a genetic impairment of MT-2 was observed to cause microcyter hypochrom anemia with low transferrin saturation (Finberg et al. 2008). Based on these findings, it can be suggested that damage in the catalytic domain of MT-2 can affect adaptation ability when iron sources in the body are lowered both in humans and in mice, and excessive hepcidin synthesis can facilitate sequestration of iron into macrophages and decreased iron absorption.

The positive and the negative regulators of the hepcidin production and its effects on iron homeostasis are summarized in Fig. 1. The extracellular trypsin-like serine protease domain at the C-terminus of MT-1 and MT-2 can be inhibited by sulfonlated 3-amidinophenylalanine-derivatives, by various cyclic peptidic inhibitors (Quinbar et al. 2013), short linear peptides with a C-terminal arginyketone moiety (Colombo et al. 2012) or dipetide derivatives containing C-terminal decarboxylated arginine mimetics (Sisay et al. 2010), or other zwitterionic amino acid derivatives (Pászti-Gere et al. 2015) such as glyphosate, which is likely to disrupt transferrin-based iron uptake (Samsel and Seneff 2016). Moreover, surfactant polyethoxylated tallow amines were also found to inhibit matriptases possibly through membrane disruption (Pászti-Gere et al. 2015). An inhibition of MT-1 and MT-2 is also achieved by sulfonlated 3-amidinophenylalanine derivatives (Hammani et al. 2012). The most potent analogues of this inhibitor-type contain an N-terminal dichloro- or dimethoxy-biphenyl-3-sulphonyl group and inhibit MT-1 in the low one-digit nanomolar range, whereas the best inhibition constants for MT-2 are close to 100 nM (Hammani et al. 2012; Pomothly et al. 2016). However, the effects of these combined MT-1/2 inhibitors on the compensation for iron homeostatic imbalances caused by dysregulated hepcidin production have not been elucidated yet.

A reliable mono- or co-culture model in an environment which ensures appropriate cell adhesion and maintains cell-cell contacts is needed to investigate the influence of drug candidates in vitro and to predict their potential hepatic effects in vivo. The assembly of hepatocytes into 3D structures contributes to the maintenance of hepatocyte function to greater extent over conventional monolayer cell systems. Hydrogel is one of the support materials for the currently available 3D environments offering an excellent basis for the development of the desired 3D cell structure (Bachmann et al. 2015). Recently, hydrogels have been widely used for pharmacological investigations, toxicity, or controlled drug release studies (Huh et al. 2011; Haycock 2010; Lee et al. 2008; Almany and Seliktar 2005; Pongrácz and Bartis 2011; Bhattacharya et al. 2012; Khademhosseini and Langer 2007).
The aim of our study was to screen the pharmacological effects of 3-amidinophenylalanine-derived protease inhibitors on iron homeostasis via hepcidin modulation in an in vitro hepatic model such as hepatocyte mono- and hepatocyte-Kupffer co-cultures. After treatment with compound MI-461, a profiling of its IL-6 and IL-8-regulating and oxidative stress-inducing properties was performed to elucidate and to predict the safety of this inhibitor. Special emphasis was laid on evaluation and comparison of the data obtained from 2D and hydrogel-assisted hepatic cell mono- and co-cultures exposed to MT-1/2 inhibition. Moreover, based on a previously described homology model of MT-2 (Sisay et al. 2010; Maurer et al. 2012), a reasonable binding mode of inhibitor MI-461 within its active site was predicted.

**Materials and methods**

**Isolation and cultivation of hepatocytes and Kupffer cells**

Hepatocytes and hepatocyte-Kupffer cell co-cultures were freshly prepared from 15 kg weighing male pigs of the Hungarian Large White breed (obtained from Dunahyb Ltd, Fadd, Hungary) (Mátiš et al. 2016). Hepatocytes and Kupffer cells were isolated by multi-step perfusion and collagenase-mediated enzymatic digestion of the caudate lobe of the liver. All animal experiments were carried out in accordance with the ethical guidelines for the care and use of laboratory animals. The study was authorized by the Animal Welfare Committee of the University of Veterinary Medicine in Budapest, Hungary. Hepatocytes were sedimented and purified by a revised low-speed centrifugation (50× g, 75 s), and Kupffer cells were obtained from the supernatants by Percoll gradient centrifugation (500× g, 20 min). As non-parenchymal cells can attach faster, Kupffer cells were seeded first on previously collagen-coated (Type I, 10 μg/cm²) 12-well Costar TC6 cell culture dishes (Corning International, Corning, NY, USA) and on 96-well microplates, the latter used for MTS assays on cell viability. Hepatocytes in mono-cultures (Hep) or hepatocytes and Kupffer cells (HepK) were seeded in cell ratio 6:1 (hepatocyte to Kupffer cell). The prepared mono- or co-cultures were incubated under humid atmosphere at 37 °C using 10% CO₂, and culture medium was exchanged 6 h after seeding. Culturing of cells was performed in Williams’ Medium E, supplemented with penicillin–streptomycin (1%), glutamine (2 mM), FBS (5%), and insulin (20 IU/ml). Fetal bovine serum (FBS) was applied during the first 24 h of culturing. Confluent mono- and co-cultures were incubated under humid atmosphere at 37 °C using 10% CO₂, and culture medium was exchanged 6 h after seeding. Culturing of cells was performed in Williams’ Medium E, supplemented with penicillin–streptomycin (1%), glutamine (2 mM), FBS (5%), and insulin (20 IU/ml). Fetal bovine serum (FBS) was applied during the first 24 h of culturing. Confluent mono- and co-cultures suitable for the further examinations were obtained after 24-h incubation. Cell lysate protein content was spectrophotometrically determined with Bio-Rad Bradford protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 595 nm with bovine serum albumin as a standard.
Hydrogel-based cell culturing

Lyophilized HydroMatrix (Sigma-Aldrich, Saint Luis, Montana, USA) was used at 0.25% concentration for hydrogel preparation. Hepatocytes and Kupffer cells were added to the hydrogel-assisted matrices at the physiological pH. The culturing of Hep and HepK cells was carried out in Williams’ E medium on hydrogel-covered 6-well polyester membrane inserts (Costar Transwell, surface area 4.67 cm²/well).

Exposure of Hep and HepK6 cells to matriptase inhibitors

Ten mM stock solutions of the inhibitors (MI-432, MI-441, MI-460, and MI-461) (Fig. 2) were kept at −20 °C. Before treatment, confluent Hep and HepK6 co-cultures were washed twice with plain medium.

The solutions of the inhibitors in phenol red free Williams’ Medium E at 50 μM (in the case of MI-461, 1, 10, 30, and 50 μM) were prepared freshly prior to each experiment from the stock solutions. It was found that the selected inhibitors can be used at 50 μM concentration safely for 24 h (cell death rate was less than 5% in controls and in treated samples) in Hep mono- and HepK6 co-cultures (Pomothy et al. 2016) using MTS assay and this concentration could be applied in further experiments to characterize the effects of MT-1/MT-2 modulation in our hepatic models for 24 h. After incubation with the inhibitors for 24 h, the mono- and co-cultures were washed twice with plain medium before being subjected to the subsequent procedures.

Hepcidin ELISA measurements

Porcine ELISA kit for hepcidin analysis was obtained from Cloud-Clone Corp. (Houston, Texas, USA). Hepcidin calibration curve was prepared using hepcidin standard solutions in different concentrations (0 pg/ml, 740 pg/ml, 2222 pg/ml, 6667 pg/ml, 20,000 pg/ml). The equation of calibration curve was the following:

\[
\text{Absorbance} = 0.000318725 \times \text{concentration}_{\text{hepcidin}} \,(\text{pg/ml}) + 0.0011 \quad \text{with} \quad R^2 = 0.9963.
\]

After 24-h lasting inhibitor treatment of the Hep and HepK6 (50 μM MI-432, MI-441, MI-460, and MI-461), the culture media from 2D and hydrogel-assisted cell matrices were collected, centrifuged (1000×g for 20 min) and diluted in PBS. For detailed elucidation of the concentration-dependent effect of MI-461 administration on hepcidin levels, 0, 1, 10, 30, and 50 μM MI-461 solutions were also added to Hep. Cell cultures were also exposed to LPS after 24-h cultivation to monitor changes in hepcidin production. The cells were incubated with LPS derived from Salmonella enterica ser. Typhimurium (1 μg/ml) (obtained from Sigma-Aldrich, Germany) for 1 h. The assay procedure was performed according to the manufacturer’s guideline. After addition of the 3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution for 15 min, the intensity of color developed is reverse proportional to the concentration of hepcidin in the sample. The absorbance values were detected at 450 nm using an EZ Read Biochrom 400 microplate reader (Biochrom Ltd, UK) and normalized to protein content of the samples.
Extracellular H$_2$O$_2$ measurement by the Amplex red method

Fluorescence ROS measurement of cell supernatant was based on the detection of H$_2$O$_2$ using the Amplex Red Hydrogen Peroxide Assay Kit (Invitrogen, Molecular Probes). To determine in which concentration range the assay can be used in quantitative manner, calibration curve was prepared using H$_2$O$_2$ solutions in different concentrations (0 μM, 0.315 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM). The equation of calibration curve was found as follows:

Fluorescence intensity = 9945.7 × concentration$_{H2O2}$ (μM) + 5135.8 with $R^2$ = 0.9972.

Following the exposure of mono- and co-cultures to MI-461 (50 μM, 24 h), the H$_2$O$_2$ concentrations in the medium were determined using a working solution of 100 μM Amplex Red and 0.2 U/ml HRP. After 30-min incubation with the dye at room temperature, the quantitative H$_2$O$_2$ contents were measured using a Victor X2 2030 fluorometer ($λ_{em}$ = 560 nm, $λ_{ex}$ = 590 nm).

IL-6 and IL-8 determination by enzyme-linked immunosorbent assays

Previous characterization of LPS-induced changes in levels of pro-inflammatory cytokines such as quantitative analyses of IL-6 and IL-8 production in Hep mono- or HepK6 co-cultures model systems was performed, and data have already been published by Mátis et al. (2016). It was ascertained that LPS challenge of porcine Hep and HepK6 resulted in increased IL-6 and IL-8 levels in cell supernatants. After 24-h long inhibitor treatment (50 μM, MI-461), Hep mono- or HepK6 co-cultures were incubated in the medium for 24 h. Culture media were collected, centrifuged (245×g for 10 min), and diluted to measure IL-6 or IL-8 levels. Changes in IL-6 or IL-8 levels were determined by porcine-specific IL-6 (Sigma-Aldrich, St Louis, MO, USA) or porcine-specific IL-8 (Invitrogen Corporation, Waltham, MA, USA) ELISA kits according to the manufacturer’s instructions. The absorbance values were detected at 450 nm using an EZ Read Biochrom 400 microplate reader (Biochrom Ltd, UK) and normalized to protein content of the samples.

Model of matriptase-2 in complex with inhibitor MI-461

The coordinates of the previously described homology model of MT-2 (Sisay et al. 2010) were superimposed with the crystal structure of thrombin in complex with inhibitor MI-432 (PDB: 4e7r) (Hammami et al. 2012) followed by the deletion of thrombin. The C-terminal amine of inhibitor MI-432 was converted into a methylurea group present in analogue MI-461 using the builder function implemented in MOE (Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group Inc., 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7) followed by an energy minimization of the inhibitor within the active site of MT-2. The minimization was performed with the MMFF94 forcefield implemented in MOE using the default parameters, whereas the structure of MT-2 was kept constant.

Statistical analysis

For statistical evaluation, R 2.11.1 software package (2010) was applied. Differences between absolute means were evaluated by one-way analysis of variance (one-way ANOVA) with post hoc Tukey test, where data were of normal distribution and homogeneity of variances was confirmed. Differences were considered significant if the p value was < 0.05 marked with * (**p < 0.001).

Results

Effects on hepcidin secretion

Hep mono- and HepK6 co-cultures embedded in the presence or absence of hydrogel matrices were exposed to 50 μM of the dual MT-1/2 inhibitors (MI-432, MI-441, MI-460, and MI-461) for 24 h, and the data were compared to untreated samples (Fig. 3). In hepatocyte 2D and hydrogel-based hepatocyte 3D cultures, MI-432, MI-441, and MI-461 caused significant elevations in hepcidin secretion ($p < 0.001$) (Fig. 3a and b). It was also found that LPS at 1 μg/ml used as positive control could significantly elevate hepcidin production ($p < 0.001$). Among the tested matriptase inhibitors, only MI-461 could increase hepcidin production in vitro at 30 μM ($p = 0.022$) and 50 μM ($p < 0.001$); thus, this compound was selected for further investigations in our study (Fig. 4).

Lack of changes in extracellular hydrogen peroxide production after MI-461 administration

After 24-h exposition of hydrogel-based hepatocyte monocultures and hepatocyte-Kupffer-cell co-cultures to 50 μM MI-461, the fluorescence intensities of Amplex red were detected. No significant changes were seen in the extracellular ROS levels in the supernatants of mono-cultures ($p = 0.197$) in the control and MI-461-treated samples. Administration of the protease inhibitor did not alter significantly the extracellular hydrogen peroxide production of the inflammatory co-culture model ($p = 0.905$) (Fig. 5).
IL-6 and IL-8 cytokine profiles of hepatocytes and hepatocyte-Kupffer cell co-cultures

IL-6 levels were not significantly altered when hepatocyte mono-cultures (Fig. 6a) and co-cultures (Fig. 6b) were treated with one of the four different MT-1/2 inhibitors (MI-432, MI-441, MI-460, MI-461) at 50 \(\mu\)M for 24 h (control in absence of inhibitors). Data are shown as average absorbance values ± SEMs (\(n = 4\)).

Significant changes were found in the hydrogel-assisted mono-culture after MT-1/2 inhibition with MI-432, MI-441, and MI-461 (\(p < 0.001\)). Treatment of 2D and 3D hepatocyte-Kupffer cell co-cultures with inhibitors did not result in significant increases in hepcidin production (each case \(p > 0.05\)).
exposed to MI-461 for 24 h in hydrogel-free (p = 0.998 in mono-cultures, p = 0.786 in co-cultures) and hydrogel-assisted systems (p = 0.934 in mono-cultures, p = 0.991 in co-cultures). The IL-8 levels did not change significantly after 24-h-long 50 μM MI-461 administration in hepatocytes independently of the presence of hydrogel-base (Fig. 6c in 2D, p = 0.053; and in hydrogel, p = 0.317). In hepatocyte-Kupffer co-culture system (Fig. 6d), IL-8 levels were slightly elevated compared to those in hepatocytes. No anti-inflammatory effect of MI-461 was detected (p = 0.051) in the hydrogel-assisted co-culture system and in co-cultures without using hydrogel (p = 0.823). There was significant increase in IL-6 levels in supernatants of co-cultures compared to those produced in hepatocytes (p < 0.001) without matriptase inhibition. Regarding the cells not exposed to MI-461 treatment, no significant differences were found in IL-8 production between hepatocyte mono- and hepatocyte-Kupffer cell co-cultures (ratio 6:1) (p > 0.05).

**Discussion**

Recently, first hepcidin agonists for the treatment of iron overload have been described based on small peptidic hepcidin analogs. Moreover, analogs of BMP6, a protein which increases hepcidin expression in vivo (Andriopoulos et al. 2009), and antisense oligonucleotides targeting MT-2 activity have been developed to enhance hepcidin activities (Ganz 2013). It is worth to note that the therapeutical oral application of Mesupron, an anti-metastatic and structurally closely related 3-hydroxyamidinophenylalanine-prodrug of the active inhibitor WX-UKI-1, seems to be safe and effective in cancer treatment. WX-UKI-1 was originally described as inhibitor of the urokinase-type plasminogen activator (uPA) (Stürzebecher 2013).
et al. 1999), but also inhibits MT-1 with similar potency ($K_i$ values for uPA 0.65 $\mu$M and for MT-1 0.37 $\mu$M, respectively).

Based on our in vitro findings with hepatocytes in conventional 2D environment and hydrogel-assisted matrices, it can be reported that the applied 3-aminophenylalanine-derived dual MT-1/2 inhibitors (MI-432, MI-441, and MI-461) at 50 $\mu$M for 24 h lead to a significant elevation of plasma hepcidin concentrations. The application of these agents might be of therapeutical importance in such diseases where too low hepcidin levels are not able to prevent excessive iron release from enterocytes, macrophages, and hepatocytes and to protect tissues from the negative consequences of iron overload.

One of these disorders is hereditary hemochromatosis, which can be formed when hepcidin expression is disturbed via mutations in the hepcidin gene itself or in the genes encoding hepcidin regulators leading to iron deposition in tissues and iron-mediated organ dysfunctions. Mutations in the genes of hepcidin or HJV can be the cause for the development of juvenile form of this disease which develops fast, and it is accompanied by severe damages including cardiomypathy and endocrinopathies (Pietrangelo 2010; Nemeth and Ganz 2009). The hepatocyte mono- and the hepatocyte-Kupffer cell co-culture in 2D environment and embedded in a hydrogel-based 3D structures provide an excellent model system for studying the in vitro effects of synthetic protease inhibitors. Porcine hepatocyte-Kupffer co-cultures were previously used for mimicking hepatic inflammation, for studying LPS-induced inflammatory responses and for screening beneficial effects of potential anti-inflammatory agents (Mátis et al. 2016). Noteworthy, discrepancies between the effects of the selected MT-1/2 inhibitors on hepcidin productions in hepatic mono- and co-cultures may suggest different mode of actions of dual MT-1/MT-2 inhibition in the case of pathophysiological conditions.

The biochemical characterization of the matriptase inhibitor MI-461 containing an N-terminal dichlorobiphenyl-3-sulfonyl group revealed that this compound did not perturbate the redox state of Hep and HepK6 cultures based on the data from extracellular hydrogen peroxide measurements when it was used at 50 $\mu$M concentration for 24 h. It was also ascertained that MI-461 did not increase the levels of two proinflammatory cytokines, IL-6 and IL-8 levels; thus, the application of MI-461 did not provoke inflammatory responses in hepatocytes and hepatocyte-Kupffer cell co-culture systems. The administration of more efficient MT-2 inhibitors might present a novel drug alternative to prevent the excessive release of inflammatory mediators and hepatic dysfunction characteristic of iron overload in Kupffer cells (Jomova and Valko 2011; She et al. 2002).

In conclusion, our in vitro pharmacological investigations revealed that combined MT-1/2 inhibition itself does not induce oxidative stress, and it can exert beneficial effects on restoration of tipped iron metabolism via regulation of hepcidin production. The different findings

---

**Fig. 7** Modeled structure of inhibitor MI-461 in complex with MT-2 indicating polar interactions as dashed lines in black. Important MT-2 residues are labeled based on the chymotrypsinogen numbering. A MT-2 is shown with its solvent exposed transparent surface colored in beige, the inhibitor is shown as stick model with carbon atoms in white.

Important MT-2 residues in the active site are given as sticks with carbons in yellow (oxygen in red, nitrogen in blue, sulfur in yellow, and chlorine in green). B View on the active site of MT-2 indicating polar interactions of MI-461 with residues Asp189, Gly219, and Gly216. The figures were prepared using PyMOL v0.98 (DeLano Scientific, San Carlos, CA).
between measurements performed on monolayer or on hydrogel matrices require further experiments, for example, by applying hepatocyte-Kupffer cell co-culture with different cell ratios or by employing various 3D cultivation methods to investigate matriptase inhibitor-caused pharmaco-toxicological effects in-depth.

It is widely accepted that MT-2 can reduce hepcidin concentrations via cleavage of hemojuvelin. Inhibition of MT-2 leads to reduced hemojuvelin cleavage (and to higher hepcidin levels) resulting in lower iron concentration in blood. No papers have been published yet which at least assume that hemojuvelin cleavage can be accomplished via thrombin, factor Xa, and MT-1. However, with a $K_i$ value of 0.073 μM inhibitor, MI-461 is only a moderately active MT-2 inhibitor and is still a relatively non-selective compound because it also inhibits MT-1 and other trypsin-like serine proteases. Therefore, the development of more potent and ideally also selective MT-2 inhibitors is required in the future. The model of inhibitor MI-461 in complex with MT-2, indicating several polar contacts which contribute to the submicromolar potency of this 3-amidinophenylalanine derivative, reveals that this inhibitor type is a suitable start structure for further lead optimization.

Acknowledgments The authors would like to acknowledge the technical support of Dr. Csaba Kövágó (Department of Pharmacology and Toxicology, University of Veterinary Medicine, Budapest, Hungary) in 3D technique. We also thank Dr. Zsuzsanna Neogrady and Dr. Gábor Mátiás (Department of University of Veterinary Medicine, Department of Physiology and Biochemistry, Budapest, Hungary) for the generous donation of mono- and co-cultures of porcine hepatocytes and Kupffer cells.

Author contribution EPG wrote the article, and ASz and TS revised it critically for important content. EPG and ASz designed the research work. GSz and EPG collected the data and did the analyses. EPG, GSz, and TS accomplished the interpretation of data. TS was responsible for development of synthesis routes and preparation of matriptase inhibitors. Molecular modelling was performed by MG.

Funding information Open access funding provided by University of Veterinary Medicine (ÁTE). This research was supported by the Hungarian Scientific Research Fund (grant no. 115685 and 124522). This project was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences. This work is supported by the European Union and co-financed by the European Social Fund (grant agreement no. EFOP-3.6.1-16-2016-00024, EFOP-3.6.2-16-2017-00012).

Compliance with ethical standards

All animal care and experimental procedures were carried out in accordance with European Union and Hungarian legislation acts relevant to animal experimentation. All procedures were performed in accordance with the ethical standards of the Local Ethics Committee for Animal Experiments in University of Veterinary Medicine, Budapest, Hungary.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Almany L, Seliktar D (2005) Biosynthetic hydrogel scaffolds made from fibrinogen and polyethylene glycol for 3D cell cultures. Biomaterials 26:2467–2477

Andriopoulos B, Corradi E, Xia Y, Faasse SA, Chen S, Gryguerevic L, Knutson MD, Pietrangelo A, Vukicevic S, Lin HY, Babitt YL (2009) BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 41:482–487

Armitage AE, Eddowes LA, Gileadi U, Cole S, Spottswood NE, Selvakumar TA, Ho LP, Townsend AR, Drakesmith H (2012) Hepcidin regulation by innate immune and infectious stimuli. Blood 118(15):4129–4139

Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY (2006) Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38:531–539

Bachmann A, Moll M, Gottwald E, Nies C, Zantl R, Wagner H, Burkhardt B, Sanchez JMM, Ladurner R, Thasler W, Damm G, Nussler AK (2015) 3D cultivation techniques for primary human hepatocytes. Microarrays 4(1):64–83

Bergner A, Bauer M, Brandstetter H, Stürzebecher J, Bode W (1995) The X-ray crystal structure of thrombin in complex with N-alpha-2-naphthylsulfonyl-L-3-amidino-phenylalanyl-4-methylpiperide: the beneficial effect of filling out an empty cavity. J Enzym Inhib 9:101–110

Bhattacharya M, Malinen MM, Lauren P, Lou YR, Kuusima SW, Kanninen L, Lille M, Corlu A, GuGuen-Guillouzo C, Ikkala O, Laukkanan A, Urtti A, Yliptonula M (2012) Nanofibrillar cellulose hydrogel promotes three-dimensional liver cell culture. J Control Release 164:291–298

Bugge TH, Antalis TM, Wu Q (2009) Type II transmembrane serine proteases. J Biol Chem 284(35):23177–23181

Colombo E, Désilets A, Duchêne D, Chagnon F, Najmanovich R, Leduc JL (2011) Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology 54:273–284

Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, Khovananth K, Mudd S, Mann N, Moresco EM, Beutler E, Beutler B (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science 320(5879):1088–1092

Finnberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, Mayo MM, Samuel SM, Strouse JJ, Markianos K, Andrews NC, Fleming MD (2008) Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 40(5):569–571

Folgueras AR, de Lara FM, Pendás AM, Garabaya C, Rodríguez F, Astudillo A, Bernal T, Cabanillas R, López-Otin C, Velasco G (2008) Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 112(6):2539–2545

Fujita N, Sugimoto R, Takeo M, Urawa N, Miufi R, Tanaka H, Kobayashi Y, Iwasa M, Watanabe S, Adachi Y, Kaito M (2007) [519]
Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. J Mol Med 13(1-2):97–104

Ganz T (2013) Systemic iron homeostasis. Physiol Rev 93(4):1721–1741

Ganz T, Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta 1823(9):1434–1443

Gao X, Campian JL, Qian M, Sun XF, Eaton JW (2009) Mitochondrial DNA damage in iron overload. J Biol Chem 284(8):4767–4775

Hammami M, Rühmann E, Maurer E, Heine A, Gütsc how M, Klege B, Steinmetzer T (2012) New 3-amidinophenylalanine-derived inhibitors of matriptase. Med Chem Commun 3:807–813

Harrison-Findik DD (2007) Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 13(37):4925–4930

Haycock JW (2010) 3D cell culture: a review of current approaches and techniques. Methods Mol Biol 695:1–15

Hooper JD, Campagnolo L, Goodarzi G, Truong TN, Stuhlmann H, Quigley JP (2003) Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues. Biochem J 373(3):689–702

Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC (2005) A mouse model of juvenile hemochromatosis. J Clin Invest 115:2187–2191

Huh D, Hamilton GA, Inger DE (2011) From 3D cell culture to organs-on-chips. Trends Cell Biol 21(12):745–754

Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283:65–87

Khademhosseini A, Langer R (2007) Microengineered hydrogels for tissue engineering. Biomaterials 28:5087–5092

Knutson MO, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M (2007) IL-6 mediates hypoferremia of inflammation by inducing hepcidin. Proc Natl Acad Sci U S A 102:1324–1328

Lee J, Cuddihy MJ, Kotov NA (2008) Three-dimensional cell culture matrices: state of the art. Tissue Eng 14(1):61–86

Máti s G, Kulcsár A, Petrilla J, Talapka P, Zs N (2016) Porcine hepatocyte-Kupffer cell co-culture as an in vitro model for testing the efficacy of anti-inflammatory substances. J Anim Physiol An N 101(2):201–207

Maurer E, Sisay MT, Stirnberg M, Steinmetzer T, Bajorath J, Güt sc h ow M (2012) Insights into matriptase-2 substrate binding and inhibition mechanisms by analyzing active-site-mutated variants. ChemMedChem 7:68–72

Molecular Operating Environment (MOE), C. C. G. I., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7 2016.

Naunyn-Schmiedeberg’s Arch Pharmacol (2020) 393:511–520

Pomothy J, Szombath G, Rokonál P, Máti s G, Zs N, Steinmetzer T, Pászti-Gere E (2016) The impact of acute matriptase inhibition in hepatic inflammatory models. Biomed Res Int. https://doi.org/10.1155/2016/630984

Pongrác z J, Bartis D (2011) “Biomaterials” in Three dimensional tissue engineering. University of Pécs, 17–19.

Quimbar P, Malik U, Sommerhoff CP, Kaas Q, Chan LY, Huang YH, Grundhüber M, Dunse K, Craik DJ, Anderson MA, Daly NL (2013) High-affinity cyclic peptide matriptase inhibitors. J Biol Chem 288(19):13885–13896

Renatus M, Bode W, Huber R, Sturzebecher J, Stubbs MT (1998) Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. J Med Chem 41:5445–5456

Samelson A, Seneff S (2012) Glycolytic pathways to modern diseases V: amino acid analogue of glycine in diverse proteins. J Biol Phys Chem 16(6):9–46

She H, Xiong S, Lin M, Zandi E, Giulivi C, Tsukamoto H (2002) Iron activates NF-B in Kupffer cells. Am J Physiol –Gastr L 283:G719–G726

Sisay MT, Steinmetzer T, Stirnberg M, Maurer E, Hammami M, Bajorath J, Gütsc h ow M (2010) Identification of the first low-molecular weight inhibitors of matriptase-2. J Med Chem 53:5523–5535

Steinmetzer T, Schweinitz A, Sturzebecher A, Dönnecke D, Uhland K, Schuster O, Steinmetzer P, Müller F, Friedrich R, Than ME, Bode W, Sturzebecher J (2006) Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem 49:4116–4126

Stirnberg M, Güt sc h ow M (2013) Matriptase-2, a regulatory protease of iron homeostasis: possible substrates, cleavage sites and inhibitors. Curr Pharm Des 19:1052–1061

Sturzebecher J, Vieweg H, Steinmetzer T, Schweinitz A, Stubbs MT, Renatus M, Wikström P (1999) 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 9(21):3147–3152

Zeslawska E, Schweinitz A, Karcher A, Sondermann P, Sper S, Sturzebecher J, Jacob U (2000) Crystals of the urokinase type plasminogen activator variant beta-c-uluPain complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol 301:465–475

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.